Literature DB >> 697143

Effect of orally administered ribavirin on experimental feline calicivirus infection in cats.

R C Povey.   

Abstract

Ribavirin administered orally at 75 mg/kg/day in 3 divided doses for 10 days, beginning either 1 or 4 days, after aerosol exposure of cats to calicivirus strain 255, failed to have any beneficial effect on the clinical course of the disease or to reduce viral excretion. Indeed, there was enhanced severity of the clinicopathologic findings in the treated exposed group, due largely to hemorrhage resulting from profound thrombocytopenia. Other toxic effects included depression of red and white blood cells, increased alanine aminotransferase activity, icterus, and body weight loss. Toxic effects were largely reversed within 1 week of cessation of treatment.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 697143

Source DB:  PubMed          Journal:  Am J Vet Res        ISSN: 0002-9645            Impact factor:   1.156


  10 in total

1.  Norovirus proteinase-polymerase and polymerase are both active forms of RNA-dependent RNA polymerase.

Authors:  Gaël Belliot; Stanislav V Sosnovtsev; Kyeong-Ok Chang; Vijay Babu; Uzo Uche; Jamie J Arnold; Craig E Cameron; Kim Y Green
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

2.  Aqueous Extracts of Hibiscus sabdariffa Calyces Decrease Hepatitis A Virus and Human Norovirus Surrogate Titers.

Authors:  Snehal S Joshi; Lezlee Dice; Doris H D'Souza
Journal:  Food Environ Virol       Date:  2015-07-05       Impact factor: 2.778

Review 3.  Calicivirus Infection in Cats.

Authors:  Regina Hofmann-Lehmann; Margaret J Hosie; Katrin Hartmann; Herman Egberink; Uwe Truyen; Séverine Tasker; Sándor Belák; Corine Boucraut-Baralon; Tadeusz Frymus; Albert Lloret; Fulvio Marsilio; Maria Grazia Pennisi; Diane D Addie; Hans Lutz; Etienne Thiry; Alan D Radford; Karin Möstl
Journal:  Viruses       Date:  2022-04-29       Impact factor: 5.818

4.  Interferons and ribavirin effectively inhibit Norwalk virus replication in replicon-bearing cells.

Authors:  Kyeong-Ok Chang; David W George
Journal:  J Virol       Date:  2007-09-12       Impact factor: 5.103

5.  Susceptibility of feline herpesvirus 1 and a feline calicivirus to feline interferon and recombinant human leukocyte interferons.

Authors:  R W Fulton; L J Burge
Journal:  Antimicrob Agents Chemother       Date:  1985-11       Impact factor: 5.191

6.  Bioluminescence technologies to detect calicivirus protease activity in cell-free system and in infected cells.

Authors:  Tomoichiro Oka; Hirotaka Takagi; Yukinobu Tohya; Kosuke Murakami; Naokazu Takeda; Takaji Wakita; Kazuhiko Katayama
Journal:  Antiviral Res       Date:  2011-02-21       Impact factor: 5.970

Review 7.  Antiviral strategies to control calicivirus infections.

Authors:  Jacques Rohayem; Mirko Bergmann; Julia Gebhardt; Ernest Gould; Paul Tucker; Andrea Mattevi; Torsten Unge; Rolf Hilgenfeld; Johan Neyts
Journal:  Antiviral Res       Date:  2010-05-21       Impact factor: 5.970

Review 8.  Efficacy of Antiviral Drugs against Feline Immunodeficiency Virus.

Authors:  Katrin Hartmann; Anita Wooding; Michèle Bergmann
Journal:  Vet Sci       Date:  2015-12-18

9.  Evaluation of free or liposome-encapsulated ribavirin for antiviral therapy of experimentally induced feline infectious peritonitis.

Authors:  R C Weiss; N R Cox; M L Martinez
Journal:  Res Vet Sci       Date:  1993-09       Impact factor: 2.534

10.  Toxicologic effects of ribavirin in cats.

Authors:  R C Weiss; N R Cox; M K Boudreaux
Journal:  J Vet Pharmacol Ther       Date:  1993-09       Impact factor: 1.786

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.